#Clinical Trials #George Clinical #Emerald Clinical

Emerald Clinical Trials – A New Era in Clinical Research

George Clinical, a prominent clinical research organization (CRO) with a global presence, has officially rebranded as Emerald Clinical Trials. This transformation is not just a change in name but signifies a strategic evolution that emphasizes the company’s established reputation for reliability, flexibility, and specialized expertise acquired over its two-decade history.

A Name That Reflects Growth

The name “Emerald” signifies renewal, hope, and healing, resonating with the organization’s mission to enhance the reliability and transparency of global clinical trials. This rebranding is a strategic response to the growing demand across clinical sectors for dependable and innovative services that can adapt to the fast-paced evolution of medical research.

Emerald Clinical Trials aims to offer comprehensive services across various therapeutic areas, with a primary focus on positively impacting patients' lives. The organization has set itself apart in areas such as oncology and cardio-renal metabolic treatment (CRM), and is well-regarded for its deep local expertise and global scientific leadership.

Bridging Global Standards with Local Expertise

With operations spanning 42 countries directly and an extensive partner network reaching 70 additional countries, Emerald Clinical Trials ensures seamless execution of clinical studies worldwide. This vast reach coupled with a commitment to maintaining high-quality standards places Emerald in a distinctive position on the global clinical research stage.

Mary Gunn, the CEO of Emerald Clinical Trials, emphasized the organization's goal over the past two decades: “Our focus has always been on providing high-quality studies by combining global reach with close contact. We deliver the expertise of a large CRO while providing the personal attention and flexibility typical of a smaller partner.” This dual approach ensures that each client, from burgeoning biotech firms to leading pharmaceutical companies, receives tailored support to mitigate risks associated with their clinical programs.

Client-Centric Approach

Emerald’s deep customer commitment fuels long-lasting relationships founded on trust, reliability, and measurable success. This dedication is further backed by a history of repeat business, industry accolades, and a consistent track record in facilitating the market introduction of therapeutic treatments. Dr. Daniel Tillett, CEO of Race Oncology and an Emerald client, noted the necessity for CROs to be agile and adaptable, stating,